Clinical Trials Logo

Pmm2-CDG clinical trials

View clinical trials related to Pmm2-CDG.

Filter by:
  • None
  • Page 1

NCT ID: NCT05549219 Recruiting - Pmm2-CDG Clinical Trials

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Start date: November 29, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric, patients with a confirmed diagnosis of PMM2-CDG. The planned doses of GLM101 to be investigated are 10, 20 and 30 mg/kg. The study will consist of a Screening Period, a 24-week (6-month) Treatment Period, and a 30-day (1-month) Follow-Up Period.

NCT ID: NCT04925960 Active, not recruiting - Pmm2-CDG Clinical Trials

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Start date: November 10, 2022
Phase: Phase 3
Study type: Interventional

This is a prospective, single-center, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and clinical and metabolic improvement of pediatric subjects with PMM2-CDG on oral epalrestat therapy vs. placebo.

NCT ID: NCT04679389 Terminated - Pmm2-CDG Clinical Trials

Acetazolamide Efficacy in Ataxia in PMM2-CDG

Start date: March 17, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Objective 1 (Primary): To determine the efficacy of acetazolamide in improving ataxia in patients with PMM2-CDG. Objective 2 (Secondary): To evaluate for any adverse events related to longer term acetazolamide administration. Objective 3 (Secondary): To examine the effect of acetazolamide on PMM2 biomarkers including carbohydrate deficient transferrin results, electrolytes (Na, K, Cl, CO2), VBG (pH, pCO2, PO2, CO2, Base excess), liver function tests (AST, ALT, GGT, indirect and direct bilirubin, total protein, albumin, alkaline phosphatase), kidney function tests (BUN, Creatinine, Urinalysis, urine calcium/creatinine ratio, urine protein/creatinine ratio), growth (height, weight, head circumference), vital signs (blood pressure, respiratory rate, heart rate), PROMIS scores, dysarthria using the PATA score, and NPCRS score. Objective 4 (Secondary): To explore characteristics of individuals with PMM2-CDG who do not respond to acetazolamide.